Biocon Secures 10-Year Pertuzumab Contract in Brazil

Bengaluru-headquartered biopharmaceutical firm Biocon Limited announced on September 8, 2026, that its consortium with Bahiafarma and Bionovis has received a 100% allocation under Brazil's 10-year Productive Development Partnership (PDP) program for the oncology drug pertuzumab. The partnership grants the consortium exclusive access to Brazil's public healthcare market, which represents approximately 70% of the national demand for the HER2-positive breast cancer treatment. The agreement highlights an international expansion milestone for Biocon and introduces a phased localization framework to support Brazil's Unified Health System (SUS).

Expansion and Market Impact in Brazil's Public Healthcare Sector

Under the terms of the agreement, Biocon will secure milestone payments and revenue shares over the 10-year lifespan of the program. Pertuzumab, a monoclonal antibody deployed in treating HER2-positive breast cancer, is not currently manufactured locally in Brazil and accounts for substantial public expenditure under the SUS. Through the PDP framework, the collaboration aims to transfer complex biological manufacturing technology, establish domestic production lines, and ensure a steady supply of affordable oncology therapies for patients across the country.

Consortium Structure and Local Partnerships

The initiative unites Biocon with Brazilian public laboratory Bahiafarma and biotechnology firm Bionovis to execute the supply contract and drive medium- to long-term phased localization. Bahiafarma operates as a public pharmaceutical laboratory under the State of Bahia focused on supplying the SUS, while Bionovis specializes in the development and commercialization of complex biological medicines and biosimilars within Brazil. Together, the consortium partners seek to reinforce Brazil's industrial health policies, generate specialized employment, and build long-term manufacturing autonomy.

Strategic Significance for Global Biopharmaceutical Operations

For Biocon, the 10-year agreement expands its international footprint and deepens its engagement in high-demand oncology segments. The integration of research, development, and manufacturing capabilities allows the company to address complex healthcare challenges in regulated international markets. By participating in national health initiatives like Brazil's PDP, Biocon reinforces its commercial strategy of scaling access to affordable biological therapies across more than 120 countries.

Official Sources Section

• Biocon Limited BSE Regulatory Filing and Press Release

• National Stock Exchange of India (NSE) Filings - Biocon Limited

Quote Section

"Brazil is an important country for Biocon, and our journey here reflects the transformative potential of strong partnerships in building local capabilities and expanding access to high-quality, affordable medicines," stated Shreehas Tambe, CEO & Managing Director, Biocon. "This long-term supply contract for pertuzumab marks a significant milestone in this journey, enabling us to reach more patients living with HER2-positive breast cancer and address an important healthcare need at scale."

Why It Matters

The agreement secures long-term revenue streams for Biocon while addressing critical oncology needs within South America's largest public healthcare market. For patients and healthcare providers in Brazil, the deal reduces import dependence for expensive biological therapies, lowers public procurement costs under the SUS, and establishes domestic manufacturing capabilities for advanced cancer treatments.

Key Facts at a Glance

• Biocon Limited formed a consortium with Bahiafarma and Bionovis to secure a 10-year contract in Brazil.

• The consortium received 100% allocation under Brazil's Productive Development Partnership (PDP) program for pertuzumab.

• The agreement provides exclusive access to Brazil's public healthcare market, covering roughly 70% of national demand.

• The partnership includes phased technology localization to manufacture the HER2-positive breast cancer therapy locally within Brazil.

Frequently Asked Questions

• What is the duration of the supply contract secured by Biocon in Brazil?

  The contract operates over a 10-year period under Brazil's Productive Development Partnership program.

• Which medical condition does the contracted drug treat?

  The product, pertuzumab, is a monoclonal antibody used in the treatment of HER2-positive breast cancer.

• Who are Biocon's partners in this initiative?

  Biocon partnered with Brazilian public laboratory Bahiafarma and biotechnology firm Bionovis.

• What proportion of Brazil's market does the agreement cover?

  The agreement grants exclusive access to Brazil's public healthcare market, which represents about 70% of the country's total demand for pertuzumab.

Source: Biocon Limited regulatory filing submitted to BSE Limited and National Stock Exchange of India Limited.